Jason Hafron, MD

Jason Hafron, MD, is the chief medical officer and medical director of clinical research at the Michigan Institute of Urology, as well as a professor of urology at the William Beaumont School of Medicine, Oakland University.

Articles by Jason Hafron, MD

Dr Hafron on a Multidisciplinary Quality Initiative Designed to Mitigate the AEs of ADT in Prostate Cancer

ByJason Hafron, MD

May 16th 2026

Jason Hafron, MD, discusses findings from a study that evaluated the implementation of a multidisciplinary quality initiative in prostate cancer.

Dr Hafron on the FDA Approval of Adjuvant Atezolizumab in MRD+ MIBC

ByJason Hafron, MD

May 15th 2026

Jason Hafron, MD, discusses the significance of the FDA approval of adjuvant atezolizumab for MRD+ muscle-invasive bladder cancer.

Jason Hafron, MD

Articles by Jason Hafron, MD

Dr Hafron on a Multidisciplinary Quality Initiative Designed to Mitigate the AEs of ADT in Prostate Cancer

Dr Hafron on the FDA Approval of Adjuvant Atezolizumab in MRD+ MIBC

Latest Updated Articles

Trending on OncLive

FDA Approves Orca-T for Matched Donor HSCT in Hematologic Malignancies

SERENA-6 Controversies Push the Breast Cancer Field to Consider the Future Role of ctDNA-Guided Treatment Decisions

SYNC-T SV-102 Employs Novel Mechanism to Target Immunologically ‘Cold’ Tumors in Advanced Metastatic Prostate Cancer

GLP-1 Receptor Agonists, Endocrine Therapy, and Metabolic Health Comprise Holistic Breast Cancer Care

FDA Approval Positions Belzutifan Plus Pembrolizumab as a New Adjuvant Standard in ccRCC